CCI approves acquisition of minority stake of BDR Pharma by Multiples Private Equity Fund III, others
The proposed combination relates to the acquisition of a minority stake by Multiples Fund III and Financial Investors in the Target.
New Delhi: The Competition Commission of India (CCI) has recently approved the acquisition of a minority stake in BDR Pharmaceuticals International Private Limited (BDR/Target) by Multiples Private Equity Fund III, SRF Transnational Holdings Limited (SRF Transnational), Balkrishna Industries Limited (BIL), Dharmayug Investments Limited (DIL), QRG Investments and Holdings Limited (QRG), Mr. Nishant K. Agarwal and Ms. Mallika Srinivasan (Acquirers).
BDR Pharmaceuticals International Private Limited is a pharmaceutical company specialised in four therapeutic segments i.e., oncology, critical care, gynecology, and neurology. It is engaged in the business of: (i) manufacture and sale of active pharmaceutical ingredients; (ii) manufacture and sale of formulations; and (iii) contract development and manufacturing services.
As per the transaction, SRF Transnational, BIL, DIL, QRG, Mr. Agarwal, and Ms. Srinivasan are collectively referred to as the 'Financial Investors'. The Multiples Fund III, Financial Investors and the Target are collectively referred to as the 'Parties'.
The proposed combination relates to acquisition of minority stake by Multiples Fund III and Financial Investors in the Target. The acquisition of equity shares of the Target and falls under Section 5(a) of the Competition Act, 2002.
Multiples Fund III is a Category II Alternative Investment Fund with the Securities and Exchange Board of India and is being managed by Multiples Alternate Asset Management Private Limited. It belongs to the Multiples group, which, through its portfolio companies, is directly or indirectly engaged in sectors including film exhibition, financial services, banking, etc. in India.
SRF Transnational is a non-banking financial company (NBFC) registered with the Reserve Bank of India (RBI). It is engaged in the business of investment in securities of other companies.
Balkrishna Industries Limited (BIL) is engaged in the business of manufacturing and selling of off-highway tyres.
Dharmayug Investments Limited (DIL) is an NBFC registered with the RBI.
QRG Investments and Holdings Limited (QRG) is an NBFC registered with the RBI and holds investments in several companies.
Mr. Nishant K. Agarwal is an independent investor.
Ms. Mallika Srinivasan is an independent investor.
Read also: BDR Pharma launches Enzalutamide under the brand name BDENZA
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd